Literature DB >> 11315085

Adaptive sample size calculations in group sequential trials.

W Lehmacher1, G Wassmer.   

Abstract

A method for group sequential trials that is based on the inverse normal method for combining the results of the separate stages is proposed. Without exaggerating the Type I error rate, this method enables data-driven sample size reassessments during the course of the study. It uses the stopping boundaries of the classical group sequential tests. Furthermore, exact test procedures may be derived for a wide range of applications. The procedure is compared with the classical designs in terms of power and expected sample size.

Mesh:

Substances:

Year:  1999        PMID: 11315085     DOI: 10.1111/j.0006-341x.1999.01286.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  70 in total

Review 1.  [Monitoring of clinical trials. Methodology, interim analyses, and end results].

Authors:  M Pritsch; K Unnebrink
Journal:  Med Klin (Munich)       Date:  1999-12-15

Review 2.  Successful aging: Advancing the science of physical independence in older adults.

Authors:  Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor
Journal:  Ageing Res Rev       Date:  2015-10-14       Impact factor: 10.895

3.  Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.

Authors:  Timothy C Guetterman; Michael D Fetters; Laurie J Legocki; Samkeliso Mawocha; William G Barsan; Roger J Lewis; Donald A Berry; William J Meurer
Journal:  Clin Res Regul Aff       Date:  2015-09-18

4.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

5.  Acupuncture treatment in irritable bowel syndrome.

Authors:  A Schneider; P Enck; K Streitberger; C Weiland; S Bagheri; S Witte; H-C Friederich; W Herzog; S Zipfel
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

6.  A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial.

Authors:  Yeonhee Park; Heather J Fullerton; Jordan J Elm
Journal:  Contemp Clin Trials       Date:  2019-10-13       Impact factor: 2.226

Review 7.  Two-stage designs in bioequivalence trials.

Authors:  Helmut Schütz
Journal:  Eur J Clin Pharmacol       Date:  2015-01-22       Impact factor: 2.953

8.  [Modern study designs and analysis methods in clinical research].

Authors:  J Gerß; M Eveslage; A Faldum; R Schmidt
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

9.  Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Ekkehard Glimm; Josephine N Khan; John A Kairalla; Nigel Stallard
Journal:  Stat Med       Date:  2020-05-03       Impact factor: 2.373

10.  Design and inference for 3-stage bioequivalence testing with serial sampling data.

Authors:  Fangrong Yan; Huihong Zhu; Junlin Liu; Liyun Jiang; Xuelin Huang
Journal:  Pharm Stat       Date:  2018-05-03       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.